These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8971678)
21. In vitro and in vivo evaluation in dogs and pigs of a hydrophilic matrix containing propylthiouracil. Kabanda L; Lefebvre RA; Van Bree HJ; Remon JP Pharm Res; 1994 Nov; 11(11):1663-8. PubMed ID: 7870687 [TBL] [Abstract][Full Text] [Related]
22. Correlation between the viscoelastic properties of the gel layer of swollen HPMC matrix tablets and their in vitro drug release. Hamed R; Al Baraghthi T; Sunoqrot S Pharm Dev Technol; 2018 Nov; 23(9):838-848. PubMed ID: 27808590 [TBL] [Abstract][Full Text] [Related]
23. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations. Rasool BK; Fahmy SA; Galeel OW Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs. Koh SK; Jeong JW; Choi SI; Kim RM; Koo TS; Cho KH; Seo KW BMC Vet Res; 2021 Sep; 17(1):295. PubMed ID: 34488750 [TBL] [Abstract][Full Text] [Related]
25. Intermittent bolus injection versus continuous infusion of furosemide in normal adult greyhound dogs. Adin DB; Taylor AW; Hill RC; Scott KC; Martin FG J Vet Intern Med; 2003; 17(5):632-6. PubMed ID: 14529128 [TBL] [Abstract][Full Text] [Related]
26. Mucoadhesive tablets for controlled release of acyclovir. Ruiz-Caro R; Gago-Guillan M; Otero-Espinar FJ; Veiga MD Chem Pharm Bull (Tokyo); 2012; 60(10):1249-57. PubMed ID: 22863800 [TBL] [Abstract][Full Text] [Related]
27. Hydroxypropyl methylcellulose based cephalexin extended release tablets: influence of tablet formulation, hardness and storage on in vitro release kinetics. Saravanan M; Sri Nataraj K; Ganesh KS Chem Pharm Bull (Tokyo); 2003 Aug; 51(8):978-83. PubMed ID: 12913240 [TBL] [Abstract][Full Text] [Related]
29. [The factors influencing metoprolol succinate release from hydroxypropyl methylcellulose matrix tablet]. Huang G; Wang R; Wang D; Zhang Z; Deng S Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Jun; 23(3):587-91. PubMed ID: 16856395 [TBL] [Abstract][Full Text] [Related]
30. Formulation and Yehualaw A; Tafere C; Yilma Z; Abrha S Biomed Res Int; 2023; 2023():4322375. PubMed ID: 37929241 [TBL] [Abstract][Full Text] [Related]
31. Mechanism of ascorbic acid enhancement of the bioavailability and diuretic effect of furosemide. Lee MG; Chiou WL Drug Metab Dispos; 1998 May; 26(5):401-7. PubMed ID: 9571221 [TBL] [Abstract][Full Text] [Related]
32. Release characteristics and in vitro-in vivo correlation of pulsatile pattern for a pulsatile drug delivery system activated by membrane rupture via osmotic pressure and swelling. Lin HL; Lin SY; Lin YK; Ho HO; Lo YW; Sheu MT Eur J Pharm Biopharm; 2008 Sep; 70(1):289-301. PubMed ID: 18539015 [TBL] [Abstract][Full Text] [Related]
33. Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet. Cho JH; Kim YI; Kim DW; Yousaf AM; Kim JO; Woo JS; Yong CS; Choi HG Eur J Pharm Sci; 2014 Apr; 54():1-7. PubMed ID: 24388864 [TBL] [Abstract][Full Text] [Related]
34. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide. Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051 [TBL] [Abstract][Full Text] [Related]
35. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. Wolf-Coporda A; Lovrić Z; Huić M; Francetić I; Vrhovac B; Plavsić F; Skreblin M Int J Clin Pharmacol Res; 1996; 16(4-5):83-8. PubMed ID: 9172005 [TBL] [Abstract][Full Text] [Related]
36. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Huang YB; Tsai YH; Yang WC; Chang JS; Wu PC; Takayama K Eur J Pharm Biopharm; 2004 Nov; 58(3):607-14. PubMed ID: 15451535 [TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo studies on HPMC-K-100 M matrices containing naproxen sodium. Kumar SM; Chandrasekar MJ; Gopinath R; Srinivasan R; Nanjan MJ; Suresh B Drug Deliv; 2007 Mar; 14(3):163-9. PubMed ID: 17454036 [TBL] [Abstract][Full Text] [Related]
38. Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release. Hiremath PS; Saha RN Drug Deliv; 2008; 15(3):159-68. PubMed ID: 18379928 [TBL] [Abstract][Full Text] [Related]